Burning Rock Biotech Q1 EPS $(0.26) Up From $(0.39) YoY, Sales $20.75M Down From $21.38M YoY
Portfolio Pulse from Benzinga Newsdesk
Burning Rock Biotech reported Q1 losses of $(0.26) per share, a 33.33% improvement from $(0.39) YoY, but sales decreased by 2.94% to $20.75M from $21.38M YoY.
May 30, 2023 | 9:37 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Burning Rock Biotech's Q1 earnings show a 33.33% improvement in EPS, but a 2.94% decrease in sales compared to last year.
Burning Rock Biotech's Q1 earnings report shows a significant improvement in EPS, which is a positive sign for investors. However, the decrease in sales may offset the positive impact of the improved EPS. As a result, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100